These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38852790)

  • 1. The solute carrier family 26 member 9 modifies rapidly progressing cystic fibrosis associated with homozygous F508del CFTR mutation.
    Luo S; Rollins S; Schmitz-Abe K; Tam A; Li Q; Shi J; Lin J; Wang R; Agrawal PB
    Clin Chim Acta; 2024 Jul; 561():119765. PubMed ID: 38852790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.
    Sato Y; Thomas DY; Hanrahan JW
    J Biol Chem; 2019 Nov; 294(48):18269-18284. PubMed ID: 31645438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of single nucleotide variants in SLC26A9 gene in patients with cystic fibrosis (p.Phe508del homozygous) and its association to Orkambi® (Lumacaftor and Ivacaftor) response in vitro.
    Santos LG; Pereira SV; Kmit AHP; Bonadia LC; Bertuzzo CS; Ribeiro JD; Mazzola TN; Marson FAL
    Gene; 2023 Jun; 871():147428. PubMed ID: 37068695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.
    Pinto MC; Quaresma MC; Silva IAL; Railean V; Ramalho SS; Amaral MD
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease.
    Gorrieri G; Zara F; Scudieri P
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separating the contributions of SLC26A9 and CFTR to anion secretion in primary human bronchial epithelia.
    Larsen MB; Choi JJ; Wang X; Myerburg MM; Frizzell RA; Bertrand CA
    Am J Physiol Lung Cell Mol Physiol; 2021 Dec; 321(6):L1147-L1160. PubMed ID: 34668421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
    Strug LJ; Gonska T; He G; Keenan K; Ip W; Boëlle PY; Lin F; Panjwani N; Gong J; Li W; Soave D; Xiao B; Tullis E; Rabin H; Parkins MD; Price A; Zuberbuhler PC; Corvol H; Ratjen F; Sun L; Bear CE; Rommens JM
    Hum Mol Genet; 2016 Oct; 25(20):4590-4600. PubMed ID: 28171547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.
    Li W; Soave D; Miller MR; Keenan K; Lin F; Gong J; Chiang T; Stephenson AL; Durie P; Rommens J; Sun L; Strug LJ
    Hum Genet; 2014 Feb; 133(2):151-61. PubMed ID: 24057835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.
    Eastman AC; Pace RG; Dang H; Aksit MA; Vecchio-Pagán B; Lam AN; O'Neal WK; Blackman SM; Knowles MR; Cutting GR
    J Cyst Fibros; 2021 Sep; 20(5):851-856. PubMed ID: 33674211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
    Bertrand CA; Mitra S; Mishra SK; Wang X; Zhao Y; Pilewski JM; Madden DR; Frizzell RA
    Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L912-L925. PubMed ID: 28360110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.
    Lam AN; Aksit MA; Vecchio-Pagan B; Shelton CA; Osorio DL; Anzmann AF; Goff LA; Whitcomb DC; Blackman SM; Cutting GR
    J Clin Invest; 2020 Jan; 130(1):272-286. PubMed ID: 31581148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SLC26A9 in patients with CF-like lung disease.
    Bakouh N; Bienvenu T; Thomas A; Ehrenfeld J; Liote H; Roussel D; Duquesnoy P; Farman N; Viel M; Cherif-Zahar B; Amselem S; Taam RA; Edelman A; Planelles G; Sermet-Gaudelus I
    Hum Mutat; 2013 Oct; 34(10):1404-14. PubMed ID: 24272871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice.
    Liu X; Li T; Riederer B; Lenzen H; Ludolph L; Yeruva S; Tuo B; Soleimani M; Seidler U
    Pflugers Arch; 2015 Jun; 467(6):1261-75. PubMed ID: 24965066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tensin 1 (TNS1) is a modifier gene for low body mass index (BMI) in homozygous [F508del]CFTR patients.
    Walton NI; Zhang X; Soltis AR; Starr J; Dalgard CL; Wilkerson MD; Conrad D; Pollard HB
    Physiol Rep; 2021 Jun; 9(11):e14886. PubMed ID: 34086412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain.
    Chang MH; Plata C; Sindic A; Ranatunga WK; Chen AP; Zandi-Nejad K; Chan KW; Thompson J; Mount DB; Romero MF
    J Biol Chem; 2009 Oct; 284(41):28306-28318. PubMed ID: 19643730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.
    Bertrand CA; Zhang R; Pilewski JM; Frizzell RA
    J Gen Physiol; 2009 Apr; 133(4):421-38. PubMed ID: 19289574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci.
    Gong J; Wang F; Xiao B; Panjwani N; Lin F; Keenan K; Avolio J; Esmaeili M; Zhang L; He G; Soave D; Mastromatteo S; Baskurt Z; Kim S; O'Neal WK; Polineni D; Blackman SM; Corvol H; Cutting GR; Drumm M; Knowles MR; Rommens JM; Sun L; Strug LJ
    PLoS Genet; 2019 Feb; 15(2):e1008007. PubMed ID: 30807572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis.
    Balázs A; Mall MA
    Front Pharmacol; 2018; 9():1112. PubMed ID: 30327603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.